Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $190 and keeps a Buy rating on the shares. The company reported positive Phase 2 TOVIA data with 73% of trial participants improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment as week 12, the analyst tells investors in a research note. The firm believes the data validates Qtorin’s clinical utility in cutaneous venous malformations while also further strengthening the case for its broader application across other mTOR- driven cutaneous conditions.